drugset
drugset / Trial / NCT05018273

Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

NCT05018273 ↗

Phase 1 Completed 26 enrolled Nykode Therapeutics ASA Genentech, Inc. · collabVaccibody AS · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A phase 1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, antigen-specific immune response and preliminary antitumor activity associated with VB10.NEO administered in combination with atezolizumab, and to identify a RP2D for VB10.NEO in combination with atezolizumab, in patients with locally advanced and metastatic tumors that have progressed after at least 1 available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable, or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care (SOC).

Timeline

Start
2021-12-21
Primary completion
2024-10-09
Completion
2024-10-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody 1200 mg Intravenous
Subject VB10.NEO Vaccine 3 mg Intramuscular
Subject VB10.NEO Vaccine 6 mg Intramuscular
Subject VB10.NEO Vaccine 9 mg Intramuscular

Indications

No indication recorded.